ION]
МО]
lper	
ogy	·
not	(eudable
₩R	no tean

		· ·				<u> </u>			Sheet 1 of 2	
Based on Form PTO-1449			ATTY. DOCKET NO. SERIAL NO.							
(3/90)			674542-2004		. 08	/955,373				
us		RENCES CITED BY APP	PIE .		APPLICANT					
(Use several sheets if necessary)		Mouritsen et al.								
OCT 1 0 2006 ()			FILING DATE	FILING DATE GROUP						
		\2	4	<u>5</u>	October 21, 19	97	1644			
		100	PARENT	U.S. PAT	ENT DOCUMENTS					
EXAMINER INITIAL	DX	OCUMENT NUMBER	.DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
M3) AA	5,92	8,644	7/27/1999	Russell-	Jones					
			, FC	REIGN P	ATENT DOCUMENTS .			L		
DOCUMENT NUMBER		DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION			
								YES	NO	
AB CYY	wo	91/16683	10/31/1991	WIPO	(-			
·		o	THER PRIOR ART	(Including	Author, Title, Date, Pertinent Pages	, Etc.)		<u> </u>		
Mh) AC		Etlinger, H.M. "Carri	er sequence selection	on – one ke	ey to successful vaccines." Immunole	ngy Today 1992,	13(2):52-55.			
MA) VD		Dalum, I. et al., "Induction of Cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope." Molecular Immunology 1997, 34(16-17):1113-1120.								
M) AE	_	Dalum, I. et al., "Therapeutic antibodies elicited by immunization against TNF-a." Nature Biotechnology 1999, 17:666-669.								
VE) AF		Hertz, M. et al., "Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma." The Journal of Immunology 2001, 167:3792-3799.								
AG		Hertz, M. et al., "Emerging therapeutic vaccines." Drug Discovery World 2000, Surring 1:49-53.								
NOW AH	15	Henz M et al, "A the	Hertz, M. et al. "A therapeutic RNAKL vaccine induces neutralizing and RANKL antibodies and prevents bone toss in evariectomized mice." ASDMR							
. AI	1	Juji, T., et al., "A now Abstracts, page \$223.	ol therapeutic vacci (Abstract)	ne that pro-	vents pathological bone destruction in	models of osteo	pomesis and RA. ASE	BMR 23 rd Annu	al Meeting	
N (W)		March 6, 2000 Press R	March 6, 2000 Press Release from M & E Biotech. "M & E Biotech licenses Autovac ™ technology to Schering-Plough Animal Health."							
AK	<u> </u>	April 17, 2000 Press Release from M & E Biotech. "M & E Biotech A/S and H. Lundbeck A/S/ enter into a research and development agreement."								
AL					Offer of shares in M & E Biotech sub					
AM		April 12, 2002 Press Re project."	elease from M & E	Biotech. "	Pharmexa announces that GlaxoSmit	hKline has exclus	sive option on HER-2	protein breast o	cancer.	
. AN		July 9, 2001 Press Release from M & E Biotech. "Pharmexa initiates phase I/II trials in breast cancer in Denmark."								
AO		August 1, 2002 Press Release from M& E Biotech. "Pharmexa presents important pre-clinical data in its AutoVac ™ HER-2 breast cancer programme.:								
AP		September 20, 2001 Press Release from M & E Biotech. "Pharmexa publishes important pre-clinical data in its AutoVac ™ IL5 asthma programme."								
AQ		September 24, 2001 Press Release from M & E Biotech. "Pharmexa initiates phase I/II trial in breast cancer in the United Kingdom."								
AR		December 17, 2001 Press Release from M & E Biotech. "Pharmexa announces AutoVac TM cancer license option."								
V AS		December 19, 2001 Pres	December 19, 2001 Press Release from M & E Biotech. "Positive change in Pharmexa's collaboration with Schering-Plough Animal Health."							
AT		Birken, S. et al., Structural and functional cludies of the tryptic core of the human chorionic gonadotropin bett-subunit." Endocrinology 1987, 121(2):657-666. (ADSTREE) : i where Net reterior i many morely (i ted								
AU		Crabb, J.W., et al., "Top 266(25):16674-16683. (Ological and epitop Abstract)	gniqqsm a	of the cellular retinal dehyde-binding			eminiy 1991,		
AMINER (JQ			DATE CONSIDERED	,) ,	107	,		
EXAMINER: Initial if n	ference con	sidered whether or not cit	ation is in confo	ann mist b	MPEP 609. Draw line through	' 1 6	, , , ,			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I '	PTO-1449	•	ATTY, DOCKET NO.	SERIAL NO.				
(3/90)			674542-2004	08/955,373				
	LIST OF RE	EFERENCES CITED BY APPLICANT	APPLICANT					
	(Use several sheets if necessary)		Mouritsen et al.					
			FILING DATE	GROUP				
	•		October 21, 1997	1644				
		OTHER PRIOR ART (Including A	uthor, Title, Date, Pertinent Pages, Etc.)					
	ΑV	Gerry E. and Conway, T.P. "Advantage of monoclonal 1984, 68(1-2):131-135. (Abstract)	onal vs. polyclonal antisera in a beta 2-microglobulin radioinummoassay." J. Immunological Methods					
	AW	Fabian, H. et al., "Comparative analysis of human and l Biochem. Biophys. Res. Comm. 1993, 197(1):232-239.	Dutch-type elzificimer beta-amyloid peptides by infrared spectroscopy and circular dichroism." (Abstract)					
	AX	Lamba, O.P. et al., "Estimation of the eccondary structuresolution by Fourier self-deconvolution and curve fit."	cture and conformation of bovine lens crystallins by infrared spectroscopy: quantitative analysisand "Biochim. Biochim. Acta. 1993, 1163(2):113-123. (Abstract)					
	AY	Klaus W. and Schomburg, D. "Solution structure of a variant of human pancreatic secretory expsin inhibitor determined by nuclear magnetic resonance spectroscopy." J. Molecular Biology 1993, 229(3):695-706.						
EXAMINER	<u> </u>		DATE CONSIDERED (107				

.00068598